Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2',2'-difluoro-2'-deoxyguanosine + ATP
ADP + 2',2'-difluoro-2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
2'-fluoro-2'-deoxyarabinosylcytidine + ATP
ADP + 2'-fluoro-2'-deoxyarabinosylcytidine 5'-phosphate
-
-
-
-
?
2'-fluoro-2'-deoxycytidine + ATP
ADP + 2'-fluoro-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
2'-O-methyl-cytidine + ATP
ADP + 2'-O-methyl-cytidine 5'-phosphate
-
-
-
-
?
2-chloro-2'-deoxyadenosine + NTP
NDP + 2-chloro-2'-deoxy-AMP
3'-O-methyl-2'-deoxycytidine + ATP
ADP + 3'-O-methyl-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
4'-thio-2'-deoxycytidine + UTP
UDP + 4'-thio-2'-deoxycytidine 5'-phosphate
-
-
-
-
?
4'-thio-beta-D-arabinofuranosylcytosine + UTP
UDP + 4'-thio-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
-
?
9-(beta-D-arabinofuranosyl)-adenine + ATP
9-(beta-D-arabinofuranosyl)-adenine 5'-phosphate + ADP
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
ATP + (E)-5-(2-bromovinyl)-2'-deoxyuridine
ADP + ?
substrate of enzyme mutant R104M/D133A, poor substrate of the wild-type enzyme
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine 5'-phosphate
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
ATP + 1-(2-deoxy-beta-D-ribofuranosyl)-isocarbostyril
ADP + ?
-
poor substrate, 1.4% of the activity with 2'-deoxycytidine
-
-
?
ATP + 1-beta-D-arabinofuranosylcytosine
ADP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
ATP + 2',2'-difluoro-2'-deoxycytidine
ADP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-monophosphate
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
ATP + 2',3'-dideoxycytidine
ADP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine
-
-
?
ATP + 2'-deoxy-3'-thiacytidine
ADP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
ATP + 2'-deoxycytidine
ADP + 2'-deoxy-CMP
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
ATP + 2,5-difluoro-4-[1-(2-deoxy-beta-L-ribofuranosyl)]-aniline
ADP + ?
-
nucleoside mimic, 14.6% of the activity with 2'-deoxycytidine
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
ATP + 5-(3-pyridyl)-2'-deoxycytidine
ADP + 5-(3-pyridyl)-2'-deoxycytidine 5'-phosphate
-
cytosolic enzyme, poor substrate
-
-
?
ATP + 5-(4-pyridyl)-2'-deoxycytidine
ADP + 5-(4-pyridyl)-2'-deoxycytidine 5'-phosphate
-
cytosolic enzyme, poor substrate
-
-
?
ATP + 5-bromodeoxycytidine
ADP + 5-bromo-dCMP
-
-
-
?
ATP + 5-iododeoxycytidine
ADP + 5-iodo-dCMP
-
-
-
?
ATP + 5-methyldeoxycytidine
ADP + 5-methyl-dCMP
-
-
-
?
ATP + 5-propynyldeoxycytidine
ADP + 5-propynyl-dCMP
-
-
-
?
ATP + adenosine
ADP + adenosine 5'-phosphate
-
-
-
-
?
ATP + arabinosyl adenine
ADP + arabinosyl adenine 5'-phosphate
-
-
-
?
ATP + arabinosyl cytosine
ADP + arabinosyl cytosine 5'-phosphate
ATP + beta-L-2',3'-dideoxy-3'-thiacytidine
ADP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + cladribine
ADP + cladribine 5'-phosphate
-
-
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
ATP + cytarabine
ADP + cytarabine 5'-phosphate
ATP + cytidine
ADP + cytidine 5'-phosphate
-
-
-
-
?
ATP + D-2'-deoxycytidine
ADP + D-2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + D-deoxycytidine
ADP + D-dCMP
-
-
-
?
ATP + D-deoxythymidine
ADP + D-dTMP
-
-
-
?
ATP + D-deoxyuridine
ADP + D-dUMP
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
ATP + deoxycytidine
ADP + ?
ATP + deoxycytidine
ADP + dCMP
ATP + deoxyguanosine
ADP + dGMP
ATP + deoxythymidine
ADP + dTMP
ATP + deoxyuridine
ADP + dUMP
ATP + dideoxythymidine
ADP + dideoxythymidine 5'-phosphate
-
-
-
?
ATP + difluoro-arabinofuranosyl adenine
ADP + difluoro-arabinofuranosyl adenine 5'-phosphate
i.e. fludarabine
-
-
?
ATP + difluorodeoxycytidine
ADP + difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
ATP + fludarabine
ADP + fludarabine 5'-phosphate
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
ATP + gemcitabine
ADP + phospho-gemcitabine
-
-
-
?
ATP + L-2',3'-dideoxy-3'-thiacytidine
ADP + L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
-
?
ATP + L-2'-deoxycytidine
ADP + L-2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + L-deoxyuridine
ADP + L-dUMP
-
-
-
?
ATP + L-thymidine
?
human dCK, in addition to being able to phosphorylate both purines and pyrimidines, has the special ability to accept L-nucleosides as substrates
-
-
?
ATP + L-thymidine
ADP + L-dTMP
-
-
-
?
ATP + lamivudine
ADP + lamivudine 5'-phosphate
ATP + thymidine
ADP + L-dTMP
-
-
-
?
ATP + thymidine
ADP + TMP
ATP + troxacitabine
ADP + troxacitabine 5'-phosphate
-
-
-
?
beta-D-3'-hydroxymethyl-2',3'dideoxycytidine + ATP
ADP + beta-D-3'-hydroxymethyl-2',3'dideoxycytidine 5'-phosphate
-
-
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
CTP + deoxycytidine
CDP + dCMP
dATP + deoxycytidine
dADP + dCMP
dCTP + 2'-deoxycytidine
dCDP + 2'-deoxy-CMP
-
only in the absence of ATP
-
-
?
dCTP + deoxycytidine
dCDP + dCMP
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
dGTP + deoxycytidine
dGDP + dCMP
dTTP + 2'-deoxycytidine
dTDP + 2'-deoxy-CMP
dTTP + deoxycytidine
dTDP + dCMP
-
-
-
-
?
dUTP + 2'-deoxycytidine
dUDP + 2'-deoxy-CMP
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
GTP + arabinosyl-adenine
GDP + arabinosyl-adenine 5'-phosphate
-
-
-
?
GTP + azacytidine
GDP + azacytidine 5'-phosphate
-
-
-
?
GTP + cladribine
GDP + cladribine 5'-phosphate
-
-
-
?
GTP + clofarabine
GDP + clofarabine 5'-phosphate
-
-
-
?
GTP + deoxycytidine
GDP + dCMP
-
optimal activity with GTP as phosphoryl donor
-
-
?
GTP + fludarabine
GDP + fludarabine 5'-phosphate
54% conversion
-
-
?
GTP + gemcitabine
GDP + gemcitabine 5'-phosphate
-
-
-
?
GTP + lamivudine
GDP + lamivudine 5'-phosphate
-
-
-
?
NTP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
NDP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
activation of the clinically relevant substrate
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
NTP + 1-beta-D-arabinosylcytosine
NDP + 1-beta-D-arabinosylcytosine 5'-phosphate
i.e. cytaribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2',2'-difluoro-2'-deoxycytidine
NDP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
NTP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
NDP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine 5'-phosphate
i.e. clofarabine, rate-limiting step in the activation of the prodrug, precursor of an effective chemotherapeutic agent for leukemias and other haematological malignancies
-
-
?
NTP + 9-beta-D-arabinofuranosyl-2-fluoroadenine
NDP + 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate
-
-
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
NTP + 9-beta-D-arabinosyl-2-fluoroadenine
NDP + 9-beta-D-arabinosyl-2-fluoroadenine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + beta-D-2'-deoxythioguanosine
NDP + ?
-
not alpha-isomer
-
-
?
NTP + clofarabine
NDP + clofarabine 5'-phosphate
-
-
-
-
?
NTP + cytarabine
?
-
-
-
-
?
NTP + cytarabine
NDP + cytarabine 5'-phosphate
-
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
NTP + deoxyadenosine
NDP + dAMP
NTP + deoxycytidine
NDP + dCMP
NTP + deoxyguanosine
NDP + dGMP
NTP + deoxythymidine
NDP + dTMP
-
mitochondrial isozyme, better than deoxycytidine, not cytosolic isozyme I
-
-
?
NTP + deoxyuridine
NDP + dUMP
NTP + gemcitabine
?
-
-
-
-
?
NTP + troxacitabine
?
activation of the clinically relevant substrate
-
-
?
UTP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
UDP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + 1-beta-D-arabinofuranosylcytosine
UDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
i.e. cytarabine
-
-
?
UTP + 2',2'-difluorodeoxycytidine
UDP + 2',2'-difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
UTP + 2-chloro-2'-deoxyadenosine
UDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
UTP + 2-chlorodeoxyadenosine
UDP + 2-chlorodeoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
UTP + 2-fluoro-9-beta-D-arabinofuranosyladenine
UDP + 2-fluoro-9-beta-D-arabinofuranosyladenine 5'-phosphate
i.e. fludarabine
-
-
?
UTP + 9-beta-D-arabinofuranosylguanine
UDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
i.e. nelarabine
-
-
?
UTP + adenosine
UDP + adenosine 5'-phosphate
-
-
-
-
?
UTP + arabinosyl adenine
UDP + arabinosyl adenine 5'-phosphate
-
-
-
?
UTP + arabinosyl cytosine
UDP + arabinosyl cytosine 5'-phosphate
UTP + beta-L-2',3'-dideoxy-3'-thiacytidine
UDP + beta-L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + beta-L-dioxolane-cytidine
UDP + beta-L-dioxolane-cytidine 5'-phosphate
antitumor drug
-
-
?
UTP + cladribine
UDP + cladribine 5'-phosphate
-
-
-
-
?
UTP + clofarabine
UDP + clofarabine 5'-phosphate
-
-
-
-
?
UTP + cytidine
UDP + cytidine 5'-phosphate
-
-
-
-
?
UTP + D-2'-deoxycytidine
UDP + D-2'-deoxycytidine 5'-phosphate
-
-
-
?
UTP + deoxyadenosine
UDP + dAMP
UTP + deoxycytidine
UDP + dCMP
UTP + deoxyguanosine
UDP + dGMP
UTP + difluoro-arabinofuranosyl adenine
UDP + difluoro-arabinofuranosyl adenine 5'-phosphate
i.e. fludarabine
-
-
?
UTP + difluorodeoxycytidine
UDP + difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine
-
-
?
UTP + fludarabine
UDP + fludarabine 5'-phosphate
UTP + fludarabine
UDP + phospho-fludarabine
-
-
-
-
?
UTP + gemcitabine
UDP + gemcitabine 5'-phosphate
-
-
-
-
?
UTP + L-2',3'-dideoxy-3'-thiacytidine
UDP + L-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
-
?
UTP + L-2'-deoxycytidine
UDP + L-2'-deoxycytidine 5'-phosphate
-
-
-
?
UTP + troxacitabine
UDP + troxacitabine 5'-phosphate
-
-
-
?
additional information
?
-
2-chloro-2'-deoxyadenosine + NTP
NDP + 2-chloro-2'-deoxy-AMP
-
-
-
-
?
2-chloro-2'-deoxyadenosine + NTP
NDP + 2-chloro-2'-deoxy-AMP
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
-
-
-
-
?
9-beta-D-arabinofuranosylguanine + NTP
NDP + 9-beta-D-arabinofuranosylguanine 5'-phosphate
-
-
-
-
?
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
ATP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
ADP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
i.e. lamivudine
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
-
-
-
-
?
ATP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
ADP + 1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine monophosphate
-
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
?
ATP + 1-beta-D-arabinosylcytosine
ADP + 1-beta-D-arabinosylcytosine 5'-phosphate
-
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
-
i.e. gemcitabine
-
-
?
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
-
i.e. gemcitabine, transport and metabolism in vivo, overview
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxy-CMP
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxy-CMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
660812, 661034, 661040, 661330, 662521, 662988, 662989, 662992, 671801, 671908, 671911, 694483, 703020, 703425, 704730, 704900, 706027 -
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
involved in nucleotide synthesis, involved in DNA repair
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
in the presence of DTT less effective than dUTP, UTP, dTTP or GTP, without DTT only less effective than dUTP
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
best phosphate donor cytosolic isozyme II and mitochondrial isozyme
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 5'-dCMP
-
best phosphate donor
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
i.e. cladribine
-
-
?
ATP + 2-chloro-2'-deoxyadenosine
ADP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
-
i.e. cladribine
-
-
?
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
i.e. cladribine
-
-
?
ATP + arabinosyl cytosine
ADP + arabinosyl cytosine 5'-phosphate
-
i.e. cytosar
-
-
?
ATP + arabinosyl cytosine
ADP + arabinosyl cytosine 5'-phosphate
i.e. cytosar
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
-
-
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
-
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
-
-
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
-
-
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
-
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
drug against acute myeloid and lymphoblastic leukemia
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
i.e. 1-beta-D-arabinofuranosylcytosine
-
-
?
ATP + cytidine
ADP + ?
-
-
-
-
?
ATP + cytidine
ADP + ?
-
poor: beta-isomer
-
-
?
ATP + cytidine
ADP + ?
-
not: alpha-isomer
-
-
?
ATP + cytidine
ADP + ?
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
-
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
key anabolic enzyme for activation of purine or pyrimidine deoxynucleosides as well as cytidine arabinoside and other anti-tumor drugs
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
highest activity
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
highest activity
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxythymidine
ADP + dTMP
lowest activity
-
-
?
ATP + deoxythymidine
ADP + dTMP
lowest activity
-
-
?
ATP + deoxyuridine
ADP + dUMP
-
-
-
?
ATP + deoxyuridine
ADP + dUMP
-
-
-
?
ATP + fludarabine
ADP + fludarabine 5'-phosphate
-
-
-
-
?
ATP + fludarabine
ADP + fludarabine 5'-phosphate
-
-
-
?
ATP + fludarabine
ADP + fludarabine 5'-phosphate
53% conversion
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
-
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
-
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
-
-
?
ATP + gemcitabine
ADP + gemcitabine 5'-phosphate
-
i.e. difluorodeoxycytidine
-
-
?
ATP + lamivudine
ADP + lamivudine 5'-phosphate
-
-
-
-
?
ATP + lamivudine
ADP + lamivudine 5'-phosphate
-
-
-
?
ATP + thymidine
ADP + TMP
-
-
-
?
ATP + thymidine
ADP + TMP
-
cytosolic enzyme, poor substrate
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
-
-
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
-
-
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
-
poor
-
-
?
CTP + 2'-deoxycytidine
CDP + 2'-deoxy-CMP
-
as good as GTP, UTP, dATP, mitochondrial isozyme
-
-
?
CTP + deoxycytidine
CDP + dCMP
-
-
-
-
?
CTP + deoxycytidine
CDP + dCMP
-
-
-
-
?
dATP + deoxycytidine
dADP + dCMP
-
-
-
-
?
dATP + deoxycytidine
dADP + dCMP
-
-
-
-
?
dCTP + deoxycytidine
dCDP + dCMP
-
-
-
-
?
dCTP + deoxycytidine
dCDP + dCMP
-
-
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
-
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
best phosphate donor
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
-
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
cytosolic isozyme I
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
best phosphate donor
-
-
?
dGTP + 2'-deoxycytidine
dGDP + 2'-deoxy-CMP
-
poor substrate of mitochondrial isozyme
-
-
?
dGTP + deoxycytidine
dGDP + dCMP
-
-
-
-
?
dGTP + deoxycytidine
dGDP + dCMP
-
-
-
-
?
dTTP + 2'-deoxycytidine
dTDP + 2'-deoxy-CMP
-
-
-
-
?
dTTP + 2'-deoxycytidine
dTDP + 2'-deoxy-CMP
-
-
-
-
?
dUTP + 2'-deoxycytidine
dUDP + 2'-deoxy-CMP
-
best phosphate donor
-
-
?
dUTP + 2'-deoxycytidine
dUDP + 2'-deoxy-CMP
-
best phosphate donor, cytosolic enzyme I, poor, mitochondrial isozyme
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
-
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
best phosphate donor
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
-
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
as good as ATP
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
as good as dGTP, dTTP or dUTP, cytosolic isozyme I
-
-
?
GTP + 2'-deoxycytidine
GDP + 2'-deoxy-CMP
-
as good as CTP, dATP or UTP, mitochondrial isozyme
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
antineoplastic agent
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
i.e. cytarabine, rate limiting enzyme in the activation of the prodrug
-
-
?
NTP + 2',2'-difluoro-2'-deoxycytidine
NDP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
best acceptor substrate, best phosphate donors: UTP or NTP-mixture, better than ATP
-
-
?
NTP + 2',2'-difluoro-2'-deoxycytidine
NDP + 2',2'-difluoro-2'-deoxycytidine 5'-phosphate
-
cytosolic isozyme I, not mitochondrial isozyme
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
substrate also termed gemcitabine
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
-
-
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
-
-
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
-
poor
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
more effective substrate than 2'-deoxyadenosine and 2'-deoxyguanosine
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, antineoplastic agent
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
-
activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
i.e. fludarabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
-
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
ATP can be replaced by GTP, dATP, dGTP or dTTP
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
i.e. 1-beta-arabinofuranosyl cytosine, L-isomer better substrate than D-isomer
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
-
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
D-isomer
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
best phosphate donors: UTP or NTP-mixture, even better than ATP
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
cytosolic isozyme I
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
no acceptor substrate for cytosolic isozyme II or mitochondrial isozyme
-
-
?
NTP + cytosine arabinoside
NDP + cytosine arabinoside 5'-monophosphate
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
641079, 641937, 641941, 641942, 641943, 641944, 641947, 641953, 641965, 641967, 722221 -
-
?
NTP + deoxyadenosine
NDP + dAMP
-
cytosolic isozyme I
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
not mitochondrial isozyme
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
-
-
-
?
NTP + deoxyadenosine
NDP + dAMP
-
poor
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
specificity
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: dCTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: guanosine
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
?
NTP + deoxycytidine
NDP + dCMP
-
in order of decreasing activity: dGTP, CTP, ATP, dATP, dTTP, UTP, GTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: beta-gamma-methylene diphosphonate analogue of dTTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: ribavirin
-
?
NTP + deoxycytidine
NDP + dCMP
-
beta-D-2'-deoxyribonucleosides are more efficient than corresponding beta-D-arabinonucleosides or beta-ribonucleosides, rather nonspecific for base moiety of nucleoside substrate
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: adenosine, uridine
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: adenosine, uridine
-
?
NTP + deoxycytidine
NDP + dCMP
-
poor substrate: beta-5-azacytidine
-
?
NTP + deoxycytidine
NDP + dCMP
-
best acceptor substrate at low substrate concentrations
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: thymidine
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
641939, 641940, 641943, 641945, 641947, 641948, 641953, 641963, 641965, 641967, 641970, 722221, 738175, 739431 -
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: dCTP
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: guanosine
-
?
NTP + deoxycytidine
NDP + dCMP
-
poor substrate: arabinosyl-CTP
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: uridine arabinoside, cytosine
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: adenosine, uridine
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: nucleoside diphosphates and their deoxy derivatives
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: phosphate
-
?
NTP + deoxycytidine
NDP + dCMP
-
enzyme shows little specificity towards phosphate donor
-
?
NTP + deoxycytidine
NDP + dCMP
-
no substrate: deoxyuridine
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxyguanosine
NDP + dGMP
-
-
-
-
?
NTP + deoxyguanosine
NDP + dGMP
-
-
-
-
?
NTP + deoxyguanosine
NDP + dGMP
-
cytosolic isozyme I
-
-
?
NTP + deoxyguanosine
NDP + dGMP
-
not mitochondrial isozyme
-
-
?
NTP + deoxyuridine
NDP + dUMP
-
mitochondrial isozyme, not cytosolic isozyme I
-
-
?
NTP + deoxyuridine
NDP + dUMP
-
cytosolic enzyme, poor substrate
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
-
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
-
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
-
-
?
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
-
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
-
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
poor
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
as good as CTP, GTP or dATP
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
best phosphate donor at low substrate levels
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxy-CMP
-
as good as CTP, GTP or dATP
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
preferred donor and acceptor substrates
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + arabinosyl cytosine
UDP + arabinosyl cytosine 5'-phosphate
-
i.e. cytosar
-
-
?
UTP + arabinosyl cytosine
UDP + arabinosyl cytosine 5'-phosphate
i.e. cytosar
-
-
?
UTP + deoxyadenosine
UDP + dAMP
-
-
-
-
?
UTP + deoxyadenosine
UDP + dAMP
-
-
-
?
UTP + deoxyadenosine
UDP + dAMP
-
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
UTP is physiological phosphate donor
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
-
?
UTP + fludarabine
UDP + fludarabine 5'-phosphate
-
-
-
-
?
UTP + fludarabine
UDP + fludarabine 5'-phosphate
13% conversion
-
-
?
additional information
?
-
-
purine deoxynucleoside activity inseparably associated with deoxycytidine kinase protein
-
-
?
additional information
?
-
-
multisubstrate enzyme, that also phosphorylates purine deoxyribonucleotides
-
-
?
additional information
?
-
-
remarkably relaxed enantioselectivity with respect to cytidine derivatives in beta configuration
-
-
?
additional information
?
-
-
several isozymes: cytosolic deoxycytidine kinase I and II, plus mitochondrial isozyme
-
-
?
additional information
?
-
-
lack of enantioselectivity for D- and L-analogues of cytidine and adenosine
-
-
?
additional information
?
-
-
presumably one common nucleoside acceptor site
-
-
?
additional information
?
-
-
enzyme exists in different conformational states with different substrate kinetic properties
-
-
?
additional information
?
-
-
reacts with both enantiomers of beta-deoxycytidine, beta-deoxyguanidine, beta-deoxyadenosine, and alpha-D-deoxycytidine is also substrate
-
-
?
additional information
?
-
-
reacts with both enantiomers of beta-deoxyadenosine, beta-arabinofuranosyl-adenine and beta-deoxyguanine
-
-
?
additional information
?
-
-
5'-phosphorylation of is a crucial step in metabolic activation of anticancer and antiviral nucleoside antimetabolites, such as cladribine, gemcitabine, cytarabine, and lamivudine
-
-
?
additional information
?
-
de novo synthesis and salvage of ribonucleotides and deoxyribonucleotides, metabolism overview, enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
resistance of cells to cytarabine is caused by dCK enzyme deficiency
-
-
?
additional information
?
-
-
the activation of the enzyme is a first step in 2-chloro-2'-deoxyadenosine-induced cytotoxicity
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
-
the enzyme is active and important in activation of several clinically important deoxynucleoside analogues used for the treatment of haematological and solid malignancies
-
-
?
additional information
?
-
-
broad substrate specificity, overview, binding of acceptor subtrates is more tightly in presence of phosphate donor molecules
-
-
?
additional information
?
-
-
dioxolane guanosine is no substrate
-
-
?
additional information
?
-
enzyme can utilizes several phosphate donors, with preference for UTP
-
-
?
additional information
?
-
-
no activity with several difluorophenyl nucleoside analogues and with 1-(2-deoxy-beta-D-ribofuranosyl)-7-iodoisocarbostyril, overview
-
-
?
additional information
?
-
substrate-enzyme interactions, overview, enzyme prefers nucleosides with sugars in the S-conformation, i.e C2'-endo-C3'-exo, binding of substrate induces conformational changes, the phosphate donor influences the acceptor substrate specificity, mechanism, overview
-
-
?
additional information
?
-
-
the enzyme shows broad substrate specificity
-
-
?
additional information
?
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
-
enzyme of the salvage pathway for deoxyribonucleotide synthesis, which provides resting cells with deoxynucleotides for DNA repair and mitochondrial DNA synthesis, important enzyme for the phosphorylation/activation of deoxynucleoside analogues, which are cytotoxic towards both replicating and indolent malignancies
-
-
?
additional information
?
-
-
essential for the synthesis of deoxynucleotides required for DNA repair and involved in deoxynucleoside analogue activation
-
-
?
additional information
?
-
-
key enzyme in the deoxynucleoside salvage pathway and in the activation of numerous nucleoside analogues used in cancer and antiviral chemotherapy
-
-
?
additional information
?
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
dCK phosphorylates all three natural deoxyribonucleosides, exhibiting the highest affinity for 2'-deoxycytidine
-
-
?
additional information
?
-
-
dCK interacts with cyclin-dependent kinase 1 (Cdk1) and the interaction inhibits Cdk1 activity both in vitro and in vivo
-
-
?
additional information
?
-
-
development and evaluation of a homogeneous fluorescence-based assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities, detailed overview
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
additional information
?
-
-
deoxycytidine kinase shows broad substrate specificity, catalyzing the phosphorylation of deoxycytidine, deoxyadenosine, and deoxyguanosine with ATP or UTP as phosphoryl donor
-
-
?
additional information
?
-
substrate specificity or wild-type an dmutant enzymes, overview
-
-
?
additional information
?
-
-
substrate specificity or wild-type an dmutant enzymes, overview
-
-
?
additional information
?
-
the human enzyme is not active with the acyclic guanine analogue acyclovir. Acyclovir binds at the dCK active site, but does so adopting a nonproductive conformation. Despite binding ACV, the enzyme remains in the open, inactive state, overview. dCK would phosphorylate acyclic guanine analogs if they can induce a similar rotation
-
-
?
additional information
?
-
-
the human enzyme is not active with the acyclic guanine analogue acyclovir. Acyclovir binds at the dCK active site, but does so adopting a nonproductive conformation. Despite binding ACV, the enzyme remains in the open, inactive state, overview. dCK would phosphorylate acyclic guanine analogs if they can induce a similar rotation
-
-
?
additional information
?
-
the enzyme shows no activity with zidovudine, stavudine, iodoxuridine, thymidine and deoxyuridine
-
-
-
additional information
?
-
-
enzyme has two separate active sites for deoxycytidine and deoxyadenosine activity
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
additional information
?
-
-
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil is no substrate. But 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine can be converted to 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil by cytidine deaminase
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 2',2'-difluorodeoxycytidine
ADP + 2',2'-difluorodeoxycytidine monophosphate
-
i.e. gemcitabine, transport and metabolism in vivo, overview
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
ATP + 2-chlorodeoxyadenosine
ADP + 2-chlorodeoxyadenosine 5'-phosphate
-
i.e. cladribine
-
-
?
ATP + 5-methyldeoxycytidine
ADP + 5-methyl-dCMP
-
-
-
?
ATP + cladribine
ADP + cladribine 5'-phosphate
-
-
-
-
?
ATP + clofarabine
ADP + clofarabine 5'-phosphate
-
-
-
-
?
ATP + cytarabine
ADP + cytarabine 5'-phosphate
-
drug against acute myeloid and lymphoblastic leukemia
-
-
?
ATP + deoxyadenosine
ADP + dAMP
ATP + deoxycytidine
ADP + ?
ATP + deoxycytidine
ADP + dCMP
ATP + deoxyguanosine
ADP + dGMP
ATP + fludarabine
ADP + fludarabine 5'-phosphate
-
-
-
-
?
ATP + L-thymidine
?
human dCK, in addition to being able to phosphorylate both purines and pyrimidines, has the special ability to accept L-nucleosides as substrates
-
-
?
NTP + (-)-beta-2',3'-dideoxy-3'-thiacytidine
NDP + (-)-beta-2',3'-dideoxy-3'-thiacytidine 5'-phosphate
activation of the clinically relevant substrate
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
NTP + 1-beta-D-arabinosylcytosine
NDP + 1-beta-D-arabinosylcytosine 5'-phosphate
i.e. cytaribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
NTP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
NDP + 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine 5'-phosphate
i.e. clofarabine, rate-limiting step in the activation of the prodrug, precursor of an effective chemotherapeutic agent for leukemias and other haematological malignancies
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
NTP + 9-beta-D-arabinosyl-2-fluoroadenine
NDP + 9-beta-D-arabinosyl-2-fluoroadenine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + deoxycytidine
NDP + dCMP
NTP + troxacitabine
?
activation of the clinically relevant substrate
-
-
?
UTP + 2',3'-dideoxycytidine
UDP + 2',3'-dideoxycytidine 5'-phosphate
-
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxy-3'-thiacytidine
UDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
-
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used for the treatment of HIV infections
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
UTP + cladribine
UDP + cladribine 5'-phosphate
-
-
-
-
?
UTP + clofarabine
UDP + clofarabine 5'-phosphate
-
-
-
-
?
UTP + deoxyadenosine
UDP + dAMP
UTP + deoxycytidine
UDP + dCMP
UTP + deoxyguanosine
UDP + dGMP
UTP + fludarabine
UDP + phospho-fludarabine
-
-
-
-
?
additional information
?
-
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxyadenosine
ADP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
involved in nucleotide synthesis, involved in DNA repair
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
ATP + 2'-deoxycytidine
ADP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
ATP + 2'-deoxyguanosine
ADP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxyadenosine
ADP + dAMP
-
-
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
-
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + ?
-
key anabolic enzyme for activation of purine or pyrimidine deoxynucleosides as well as cytidine arabinoside and other anti-tumor drugs
-
-
?
ATP + deoxycytidine
ADP + ?
-
key enzyme in anabolic phosphorylation of deoxyribonucleosides and their analogues
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
-
?
ATP + deoxycytidine
ADP + dCMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
ATP + deoxyguanosine
ADP + dGMP
-
-
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
antineoplastic agent
-
-
?
NTP + 1-beta-D-arabinofuranosylcytosine
NDP + 1-beta-D-arabinofuranosylcytosine 5'-phosphate
i.e. cytarabine, rate limiting enzyme in the activation of the prodrug
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
i.e. gemcitabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of solid malignant tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
i.e. gemcitabine, rate limiting enzyme in the activation of the pharmaceutically relevant substrate which is commonly used in the treatment of tumors
-
-
?
NTP + 2',2'-difluorodeoxycytidine
NDP + 2',2'-difluorodeoxycytidine 5'-phosphate
-
substrate also termed gemcitabine
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2',3'-dideoxycytidine
NDP + 2',3'-dideoxycytidine 5'-phosphate
i.e. zalcitabine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
antiviral agent
-
-
?
NTP + 2'-deoxy-3'-thiacytidine
NDP + 2'-deoxy-3'-thiacytidine 5'-phosphate
i.e. lamivudine, activation of the pharmaceutically relevant substrate which is used in the treatment of HIV infections
-
-
?
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
NTP + 2'-deoxyadenosine
NDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
more effective substrate than 2'-deoxyadenosine and 2'-deoxyguanosine
-
-
?
NTP + 2'-deoxycytidine
NDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
NTP + 2'-deoxyguanosine
NDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
i.e. cladribine, antineoplastic agent
-
-
?
NTP + 2-chloro-2'-deoxyadenosine
NDP + 2-chloro-2'-deoxyadenosine 5'-phosphate
-
phosphorylation of chemotherapeutically important nucleoside analogues
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
-
activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + 9-beta-D-arabinosyl 2-fluoroadenine
NDP + 9-beta-D-arabinosyl 2-fluoroadenine 5'-phosphate
i.e. fludarabine, activation of the pharmaceutically relevant substrate which is commonly used in the treatment of lymphoproliferative malignancies
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
?
NTP + deoxycytidine
NDP + dCMP
-
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxyadenosine
UDP + 2'-deoxyadenosine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
preferred donor and acceptor substrates
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + 2'-deoxycytidine
UDP + 2'-deoxycytidine 5'-phosphate
-
rate-limiting reaction in the salvage of deoxyribonucleosides, supplying cells with deoxyribonucleotides for DNA replicative and repair synthesis
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
-
-
-
?
UTP + 2'-deoxyguanosine
UDP + 2'-deoxyguanosine 5'-phosphate
rate-limiting reaction in the salvage of deoxyribonucleosides
-
-
?
UTP + deoxyadenosine
UDP + dAMP
-
-
-
-
?
UTP + deoxyadenosine
UDP + dAMP
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
-
-
?
UTP + deoxycytidine
UDP + dCMP
-
UTP is physiological phosphate donor
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
-
?
UTP + deoxyguanosine
UDP + dGMP
-
-
-
?
additional information
?
-
-
5'-phosphorylation of is a crucial step in metabolic activation of anticancer and antiviral nucleoside antimetabolites, such as cladribine, gemcitabine, cytarabine, and lamivudine
-
-
?
additional information
?
-
de novo synthesis and salvage of ribonucleotides and deoxyribonucleotides, metabolism overview, enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
enzyme is active and medically important in anticancer and antiviral therapy due to high phosphorylation activity of prodrugs, overview
-
-
?
additional information
?
-
-
resistance of cells to cytarabine is caused by dCK enzyme deficiency
-
-
?
additional information
?
-
-
the activation of the enzyme is a first step in 2-chloro-2'-deoxyadenosine-induced cytotoxicity
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
additional information
?
-
-
the enzyme is active and important in activation of several clinically important deoxynucleoside analogues used for the treatment of haematological and solid malignancies
-
-
?
additional information
?
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway, key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy
-
-
?
additional information
?
-
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
dCK is able to phosphorylate both D- and L-nucleosides and nucleoside analogs
-
-
?
additional information
?
-
-
enzyme of the salvage pathway for deoxyribonucleotide synthesis, which provides resting cells with deoxynucleotides for DNA repair and mitochondrial DNA synthesis, important enzyme for the phosphorylation/activation of deoxynucleoside analogues, which are cytotoxic towards both replicating and indolent malignancies
-
-
?
additional information
?
-
-
essential for the synthesis of deoxynucleotides required for DNA repair and involved in deoxynucleoside analogue activation
-
-
?
additional information
?
-
-
key enzyme in the deoxynucleoside salvage pathway and in the activation of numerous nucleoside analogues used in cancer and antiviral chemotherapy
-
-
?
additional information
?
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
phosphorylates both pyrimidine and purine deoxynucleosides, including numerous nucleoside analogue anticancer and antiviral prodrugs
-
-
?
additional information
?
-
-
dCK phosphorylates all three natural deoxyribonucleosides, exhibiting the highest affinity for 2'-deoxycytidine
-
-
?
additional information
?
-
-
dCK interacts with cyclin-dependent kinase 1 (Cdk1) and the interaction inhibits Cdk1 activity both in vitro and in vivo
-
-
?
additional information
?
-
-
development and evaluation of a homogeneous fluorescence-based assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities, detailed overview
-
-
?
additional information
?
-
the earliest nucleotide kinase in evolution, probably encoded by the so-called dCK/dGK/TK2-like gene, is the progenitor gene, several duplications of it are the reason for evolutionary occurrence of nucleoside kinases with strict substrate specificities in other organism, phylogenetic tree, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-(5-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)-2-methoxyphenoxy)-2-methylpropan-2-ol
-
1-[5-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]propan-2-ol
-
2'-deoxy-5-fluorocytidine
-
-
2,2'-[[4-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-1,2-phenylene]bis(oxy)]di(ethan-1-ol)
-
2-(((2-(3-(2-fluoroethoxy)-4-methoxyphenyl)-5-methylthiazol-4-yl)methyl)thio)pyrimidine-4,6-diamine
-
2-(((2-(3-(2-fluoroethoxy)-4-methoxyphenyl)-5-propylthiazol-4-yl)methyl)thio)pyrimidine-4,6-diamine
-
2-(2-[1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]ethoxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]methoxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(2-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(2-ethylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(3-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(4-chloro-2-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(4-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([1-[6-(biphenyl-2-yloxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
-
-
2-([6-[4-(4-amino-2-oxopyrimidin-1(2H)-yl)piperidin-1-yl]-5-fluoropyrimidin-4-yl]oxy)benzonitrile
-
-
2-([[2-(3,5-difluorophenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(3-fluorophenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(3-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(4-ethoxy-3-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(4-fluorophenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine
-
2-([[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(4-methylphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-([[2-(5-bromo-2-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
-
2-[(2[-[3-(2-fluoroethoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-bromopyrimidin-4-yl)oxy]benzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-methylpyrimidin-4-yl)oxy]benzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]-5-methoxybenzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-methylpyrimidin-4-yl)oxy]benzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]-5-methoxybenzonitrile
-
-
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]benzonitrile
-
-
2-[(6-[4-[(4-aminopyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
-
-
2-[([2-[3-(2-fluoroethoxy)-4-(fluoromethoxy)phenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-methyl-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-propyl-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[3-(2-fluoroethoxy)-4-methylphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[3-(3-fluoropropoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[4-(2-fluoroethoxy)-2-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[4-(2-fluoroethoxy)-3-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[4-ethoxy-3-(2-fluoroethoxy)phenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([2-[5-(2-fluoroethoxy)-2-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[([5-ethyl-2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
-
2-[3-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-5-fluorophenoxy]ethan-1-ol
-
2-[3-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)phenoxy]ethan-1-ol
-
2-[5-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-fluorophenoxy]ethan-1-ol
-
2-[5-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethan-1-ol
-
2-[5-(4-[[(4-aminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]ethan-1-ol
-
2-[[(2-phenyl-1,3-thiazol-4-yl)methyl]sulfanyl]pyrimidine
-
2-[[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]oxy]-5-fluoropyrimidin-4-amine
-
-
3'-O-methyl-2'deoxycytidine
-
-
3'-[[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]sulfamoyl]biphenyl-4-carboxamide
-
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-fluoropyrimidin-4-yl)oxy]-4-methoxybenzonitrile
-
-
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]-4-methoxybenzonitrile
-
-
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
-
-
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]benzonitrile
-
-
3-[5-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenoxy]propan-1-ol
-
4'-thio-beta-D-arabinofuranosylcytosine
-
IC50 0.000024 mM
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
5'-O-ethyl-2'-deoxycytidine
-
-
5'-O-methyl-2'-deoxycytidine
-
-
5-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-2-methoxyphenol
-
5-chloro-4'-thio-beta-D-arabinofuranosylcytosine
-
IC50 0.051 mM
5-Fluoro-2'-deoxycytidine
5-fluoro-2-([1-[5-fluoro-6-(4-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(2-fluorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(2-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(2-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(3-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(4-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-([1-[6-(4-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
-
-
5-fluoro-2-[[1-(6-phenoxypyrimidin-4-yl)piperidin-4-yl]oxy]pyrimidin-4-amine
-
-
5-fluoro-4'-thio-beta-D-arabinofuranosylcytosine
-
IC50 0.0000020 mM
adenosine arabinoside
-
weak, not with deoxyadenosine as substrate
alpha-D-2'-Deoxythioguanosine
-
-
Cytosine arabinoside monophosphate
-
strong
Cytosine arabinoside triphosphate
GSSG
-
thiol reagents protect or reverse
H-7
-
reduces the enzyme activation caused by the addition of 2-chloro-2-deoxyadenosine
lambda protein phosphatase
-
-
LP-375752
-
i.e. 2-[4-(6-benzo[b]thiophen-2-yl-pyrimidin-4-yl)-piperazin-1-yl]-1-pyrrolidin-1-yl-ethanone
LP-503392
-
i.e. 2-thio-2'-deoxycytidine
N-(2-(5-(4-(((4,6-diaminopyrimidin-2-yl)thio)methyl)-5-propylthiazol-2-yl)-2-methoxyphenoxy)ethyl)methanesulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-2',4'-dichlorobiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-2'-chlorobiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3'-chlorobiphenyl-3-carboxamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3'-chlorobiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3-bromobenzenesulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4''-chloro-2''-methyl-1,1':4',1''-terphenyl-3-carboxamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4''-chloro-2''-methyl-1,1':4',1''-terphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-(methylsulfonyl)biphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-chlorobiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-cyanobiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-formylbiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-carboxamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methylbiphenyl-3-sulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-(1-benzothiophen-2-yl)pyridine-2-carboxamide
potent, selective, and orally bioavailable inhibitor of dCK
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-bromobenzenesulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-nitrobenzenesulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]benzenesulfonamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]biphenyl-3-carboxamide
-
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]biphenyl-3-sulfonamide
-
N-[2-[3-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)-5-fluorophenoxy]ethyl]methanesulfonamide
-
N-[2-[3-(4-[[(4,6-diaminopyrimidin-2-yl)sulfanyl]methyl]-5-propyl-1,3-thiazol-2-yl)phenoxy]ethyl]methanesulfonamide
-
NaCl
-
at 0.2-0.4 M, stimulation of 2-deoxycytidine and 2-chlorodeoxyadenosine phosphorylation, but inhibition of 2-deoxyguanosine phosphorylation
Non-substrate inhibitors
-
-
-
Nucleoside analogs
-
related to deoxycytidine, deoxyadenosine or deoxyguanosine
p-chloromercuribenzoate
-
thiol reagents protect or reverse
P1,P4-diadenosine 5'-tetraphosphate
-
not di-, tri- or pentaphosphate derivative
protein phosphatase lambda
-
-
-
Sodium diphosphate
-
not monophosphate
staurosporine
-
reduces the enzyme activation caused by the addition of 2-chloro-2-deoxyadenosine
Substrate derivatives
-
overview
-
suramin
-
no effect in unirradiated cells, complete abolishment of UV-C light induced activation
Trypsin
-
substrates or dNTP protect corresponding active site
-
Uridine arabinoside
-
weak, cytosolic isozyme I
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
-
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
-
-
5-Fluoro-2'-deoxycytidine
competitive inhibitor
5-Fluoro-2'-deoxycytidine
-
-
ADP
-
not
CMP
-
not
CTP
-
-
CTP
-
strong, ATP as substrate
cytidine
-
cytosine arabinoside as substrate
cytidine
-
deoxycytidine as substrate
cytosine arabinoside
-
deoxycytidine as substrate
cytosine arabinoside
-
deoxyguanosine as substrate
cytosine arabinoside
-
ATP as substrate; deoxycytidine as substrate; strong, deoxyadenosine as substrate
cytosine arabinoside
-
deoxycytidine as substrate
cytosine arabinoside
-
IC50 0.0000055 mM
cytosine arabinoside
-
deoxycytidine as substrate
Cytosine arabinoside triphosphate
-
strong
Cytosine arabinoside triphosphate
-
-
Cytosine arabinoside triphosphate
-
weak
dAMP
-
not
dATP
-
strong
dCDP
-
-
dCDP
-
strong, ATP as substrate
dCMP
-
-
dCMP
-
ATP as substrate; product inhibition, strong
dCMP
-
dTTP reverses; product inhibition, strong
dCMP
-
only cytosolic isozyme I; product inhibition, strong
dCMP
-
product inhibition, strong
dCTP
-
-
dCTP
-
reversible by dTTP; reversible by UTP, dUTP
dCTP
-
kinetics; reversible by dTTP; reversible by UDP
dCTP
-
no reversion by beta-gamma-methylene diphosphonate analogue of dTTP
dCTP
-
cytosine arabinoside as substrate; isozyme II
dCTP
-
no inhibition at physiological concentrations
dCTP
-
cytosine arabinoside as substrate
dCTP
-
at 0.013 mM, substrates ATP, deoxycytosine, 30% inhibition
dCTP
feedback inhibition, competitive versus phosphate donors
dCTP
-
feedback inhibition
dCTP
-
a potent inhibitor of the enzyme when ATP is the phosphoryl donor, but a relatively weak inhibitor when the enzyme activity is measured with UTP as the phosphoryl donor. Inhibition is higher with respect to cladribine than deoxycytidine
dCTP
-
about 70% inhibition at 0.2 mM
dCTP
-
ATP as substrate; moderate phosphate donor in the absence of ATP
dCTP
-
strong, pH-dependent
dCTP
-
at 0.013 mM, substrates ATP, deoxycytosine, 50% inhibition
deoxyadenosine
-
not
deoxyadenosine
-
cytosine arabinoside or deoxyguanosine as substrate
deoxyadenosine
-
cytosolic isozyme I, weak
deoxyadenosine
-
deoxycytidine
deoxyadenosine
-
cytosolic isozyme I, weak; deoxycytidine; kinetics
deoxycytidine
-
cytosine arabinoside as substrate
deoxycytidine
-
cytosine arabinoside as substrate; deoxyadenosine as substrate; deoxyguanosine as substrate
deoxycytidine
-
cytidine as substrate; deoxyguanosine as substrate
deoxycytidine
-
deoxyadenosine as substrate
deoxycytidine
-
cytosine arabinoside as substrate
deoxycytidine
-
deoxyadenosine as substrate; deoxyguanosine as substrate
deoxycytidine
-
cytosine arabinoside as substrate
deoxycytidine
-
at concentrations greater than 0.003 mM, UTP as substrate, noncompetitive
deoxyguanosine
-
not
deoxyguanosine
-
cytosine arabinoside as substrate
deoxyguanosine
-
deoxyguanosine as substrate, cytosolic isozyme I, weak
deoxyguanosine
-
deoxycytidine as substrate
deoxythymidine
-
cytosolic isozyme I, not
dGDP
-
strong
dGMP
-
strong
dGTP
-
-
dTDP
-
-
dTTP
-
at increased deoxycytidine concentrations
dTTP
-
ATP as substrate; weak
dTTP
-
only mitochondrial isozyme; strong
dTTP
-
ATP as substrate; weak
dUDP
-
strong
dUDP
-
only cytosolic isozyme I; strong
dUMP
-
not
GDP
-
not
GTP
-
-
GTP
-
not, deoxyadenosine as substrate; weak, ATP and deoxycytidine as substrate
GTP
-
not, deoxyadenosine as substrate
HgCl2
-
-
HgCl2
-
strong, thiol reagents protect
N-ethylmaleimide
-
thiol reagents protect or reverse
Nucleosides
-
overview, ATP and deoxyadenosine or deoxycytidine as substrate
UDP
-
-
UDP
-
only cytosolic isozyme I; strong
UMP
-
not
UTP
-
-
UTP
-
ATP as substrate; not with deoxyadenosine as substrate
UTP
-
not mitochondrial isozyme
additional information
-
little or no inhibition by AMP, dTMP, adenosine, guanosine; little or no inhibition by deoxyuridine
-
additional information
-
no inhibition by ribavirin
-
additional information
-
little or no inhibition by AMP, dTMP, adenosine, guanosine
-
additional information
-
deoxycytidine phosphorylating ability shows different inhibition pattern than deoxyadenosine activity
-
additional information
-
little or no inhibition by AMP, dTMP, adenosine, guanosine; little or no inhibition by deoxyuridine; little or no inhibition by ribavirin; no inhibition by inosine, xanthosine, S-adenosylhomocysteine, S-adenosylmethionine; no inhibition by uridine, thymidine; overview
-
additional information
-
activity of enzyme is reduced by hyperosmotic treatment of cells
-
additional information
-
little or no inhibition by deoxyuridine; no inhibition by TTP; no inhibition by uridine, thymidine; relatively insensitive to SH-inhibitors and detergents
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.003 - 0.015
(-)-beta-2',3'-dideoxy-3'-thiacytidine
0.00076
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)cytosine
-
pH 7.6, 37°C, recombinant enzyme
0.00654
1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-bromocytosine
-
pH 7.6, 37°C, recombinant enzyme
0.00061
1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-chlorocytosine
-
pH 7.6, 37°C, recombinant enzyme
0.00102
1-(2'-deoxy-2'-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine
-
pH 7.6, 37°C, recombinant enzyme
0.003 - 0.024
1-beta-D-arabinofuranosylcytosine
0.0131 - 0.1365
1-beta-D-arabinosylcytosine
0.0062 - 0.015
2',2'-difluorodeoxycytidine
0.15 - 0.67
2',3'-dideoxycytidine
0.0085 - 1.437
2'-deoxyadenosine
0.00005 - 0.0089
2'-deoxycytidine
0.021 - 2.266
2'-deoxyguanosine
0.0013
2,5-difluoro-4-[1-(2-deoxy-beta-L-ribofuranosyl)]-aniline
-
pH 7.6, 37°C, recombinant enzyme
0.00099 - 0.024
2-chloro-2'-deoxyadenosine
0.0051 - 0.078
2-chlorodeoxyadenosine
0.00032
4'-thio-2'-deoxycytidine
-
cosubstrate ATP 37°C, pH 8.0
0.02 - 0.088
4'-thio-beta-D-arabinofuranosylcytosine
2 - 5
9-beta-D-arabinofuranosylguanine
0.00041 - 0.015
beta-D-arabinofuranosylcytosine
0.00065 - 0.0155
cladribine
0.0087 - 0.0325
clofarabine
0.0013
CTP
-
cosubstrate 2'-deoxycytidine, 37°C, pH 7.4
0.0282
cytarabine
-
wild type enzyme, pH and temperature not specified in the publication
0.002 - 0.04
cytosine arabinoside
0.0243 - 0.144
D-thymidine
0.093 - 0.89
deoxyadenosine
0.00007 - 0.071
deoxycytidine
12.457 - 18.546
deoxythymidine
7.502 - 15.081
deoxyuridine
0.001
dTTP
-
cosubstrate 2'-deoxycytidine, 37°C, pH 7.4
0.028 - 0.551
fludarabine
0.0161 - 0.0562
gemcitabine
0.0009
GTP
-
cosubstrate 2'-deoxycytidine, 37°C, pH 7.4
0.0178 - 0.138
L-thymidine
0.00388 - 3.485
thymidine
0.011 - 0.058
troxacitabine
additional information
additional information
-
0.003
(-)-beta-2',3'-dideoxy-3'-thiacytidine
wild type enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.008
(-)-beta-2',3'-dideoxy-3'-thiacytidine
C9S/C45S/C59S/C146S mutant enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.008
(-)-beta-2',3'-dideoxy-3'-thiacytidine
wild type enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.015
(-)-beta-2',3'-dideoxy-3'-thiacytidine
C9S/C45S/C59S/C146S mutant enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.003
1-beta-D-arabinofuranosylcytosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.003
1-beta-D-arabinofuranosylcytosine
wild type enzyme with UTP as cosubstrate
0.0059
1-beta-D-arabinofuranosylcytosine
wild-type, pH 7.5, 25°C
0.007
1-beta-D-arabinofuranosylcytosine
wild type enzyme with ATP as cosubstrate
0.013
1-beta-D-arabinofuranosylcytosine
residues 65-79 deletion mutant with ATP as cosubstrate
0.024
1-beta-D-arabinofuranosylcytosine
mutant S74E, pH 7.5, 25°C
0.0131
1-beta-D-arabinosylcytosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0506
1-beta-D-arabinosylcytosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.1365
1-beta-D-arabinosylcytosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0062
2',2'-difluorodeoxycytidine
wild-type, pH 7.5, 25°C
0.0146
2',2'-difluorodeoxycytidine
wild-type
0.015
2',2'-difluorodeoxycytidine
mutant S74E, pH 7.5, 25°C
0.15
2',3'-dideoxycytidine
-
cosubstrate UTP, 37°C, pH 7.6
0.23
2',3'-dideoxycytidine
-
cosubstrate ATP, 37°C, pH 7.6
0.48
2',3'-dideoxycytidine
-
cosubstrate UTP, 37°C, pH 7.6
0.67
2',3'-dideoxycytidine
-
cosubstrate ATP, 37°C, pH 7.6
0.0085
2'-deoxyadenosine
cosubstrate UTP, pH 7.5, 37°C
0.013
2'-deoxyadenosine
wild type enzyme with UTP as cosubstrate
0.019
2'-deoxyadenosine
-
cosubstrate UTP, 37°C, pH 7.6
0.053
2'-deoxyadenosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.081
2'-deoxyadenosine
wild-type, pH 7.5, 37°C
0.081
2'-deoxyadenosine
wild-type, pH 7.5, 30°C
0.091
2'-deoxyadenosine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
0.1
2'-deoxyadenosine
wild type enzyme with ATP as cosubstrate
0.1146
2'-deoxyadenosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.115
2'-deoxyadenosine
cosubstrate ATP, pH 7.5, 37°C
0.1169
2'-deoxyadenosine
wild-type, pH 7.5, 25°C
0.15
2'-deoxyadenosine
-
cosubstrate UTP, 37°C, pH 7.6
0.1623
2'-deoxyadenosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.231
2'-deoxyadenosine
mutant R104Q/D133G, pH 7.5, 30°C
0.398
2'-deoxyadenosine
mutant R104M/D133S, pH 7.5, 37°C
0.412
2'-deoxyadenosine
mutant R104M/D133A, pH 7.5, 37°C
0.415
2'-deoxyadenosine
residues 65-79 deletion mutant with ATP as cosubstrate
0.452
2'-deoxyadenosine
mutant R104M/D133N, pH 7.5, 37°C
0.48
2'-deoxyadenosine
-
cosubstrate ATP, 37°C, pH 7.6
0.518
2'-deoxyadenosine
mutant S74E, pH 7.5, 25°C
0.532
2'-deoxyadenosine
mutant R104Q/D133N, pH 7.5, 30°C
0.55
2'-deoxyadenosine
-
cosubstrate ATP, 37°C, pH 7.6
0.598
2'-deoxyadenosine
mutant A100V/R104M/D133A, pH 7.5, 37°C
0.691
2'-deoxyadenosine
mutant R104M/D133T, pH 7.5, 37°C
0.843
2'-deoxyadenosine
mutant A100V/R104M/D133S, pH 7.5, 37°C
1.04
2'-deoxyadenosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
1.437
2'-deoxyadenosine
mutant A100V/R104M/D133T, pH 7.5, 37°C
0.00005
2'-deoxycytidine
-
cosubstrate UTP, 37°C, pH 7.6
0.0001
2'-deoxycytidine
-
cosubstrate UTP, 37°C, pH 7.6
0.00016
2'-deoxycytidine
-
cosubstrate ATP, 37°C, pH 7.6
0.00016
2'-deoxycytidine
with ATP as cosubstrate
0.00018
2'-deoxycytidine
-
cosubstrate ATP, 37°C, pH 7.6
0.001
2'-deoxycytidine
-
-
0.001
2'-deoxycytidine
-
pH 7.6, 37°C, recombinant enzyme
0.001
2'-deoxycytidine
less than 0.001 mM, residues 65-79 deletion mutant with UTP as cosubstrate
0.001
2'-deoxycytidine
less than 0.001 mM, wild type enzyme with ATP as cosubstrate
0.001
2'-deoxycytidine
less than 0.001 mM, wild type enzyme with UTP as cosubstrate
0.0014
2'-deoxycytidine
residues 65-79 deletion mutant with ATP as cosubstrate
0.0017
2'-deoxycytidine
wild-type, pH 7.5, 25°C
0.003
2'-deoxycytidine
Km below 0.003 mM, wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0057
2'-deoxycytidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.008
2'-deoxycytidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0089
2'-deoxycytidine
mutant S74E, pH 7.5, 25°C
0.021
2'-deoxyguanosine
wild type enzyme with UTP as cosubstrate
0.041
2'-deoxyguanosine
cosubstrate UTP, pH 7.5, 37°C
0.079
2'-deoxyguanosine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
0.081
2'-deoxyguanosine
mutant R104Q/D133G, pH 7.5, 30°C
0.087
2'-deoxyguanosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.154
2'-deoxyguanosine
wild-type, pH 7.5, 37°C
0.155
2'-deoxyguanosine
wild-type, pH 7.5, 30°C
0.181
2'-deoxyguanosine
cosubstrate ATP, pH 7.5, 37°C
0.231
2'-deoxyguanosine
wild type enzyme with ATP as cosubstrate
0.231
2'-deoxyguanosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.24
2'-deoxyguanosine
mutant R104Q/D133N, pH 7.5, 30°C
0.2458
2'-deoxyguanosine
wild-type, pH 7.5, 25°C
0.324
2'-deoxyguanosine
mutant R104M/D133N, pH 7.5, 37°C
0.474
2'-deoxyguanosine
residues 65-79 deletion mutant with ATP as cosubstrate
0.602
2'-deoxyguanosine
mutant S74E, pH 7.5, 25°C
0.739
2'-deoxyguanosine
mutant A100V/R104M/D133S, pH 7.5, 37°C
1.164
2'-deoxyguanosine
mutant A100V/R104M/D133T, pH 7.5, 37°C
1.172
2'-deoxyguanosine
mutant R104M/D133S, pH 7.5, 37°C
1.203
2'-deoxyguanosine
mutant R104M/D133T, pH 7.5, 37°C
1.28
2'-deoxyguanosine
mutant R104M/D133A, pH 7.5, 37°C
1.364
2'-deoxyguanosine
mutant A100V/R104M/D133A, pH 7.5, 37°C
1.865
2'-deoxyguanosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
2.266
2'-deoxyguanosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.00099
2-chloro-2'-deoxyadenosine
-
cosubstrate UTP, 37°C, pH 7.6
0.004
2-chloro-2'-deoxyadenosine
A119G mutant enzyme, 37°C, pH 7.4
0.004
2-chloro-2'-deoxyadenosine
P122S mutant enzyme, 37°C, pH 7.4
0.006
2-chloro-2'-deoxyadenosine
wild type enzyme, 37°C, pH 7.4
0.0063
2-chloro-2'-deoxyadenosine
-
cosubstrate UTP, 37°C, pH 7.6
0.009
2-chloro-2'-deoxyadenosine
I24V mutant enzyme, 37°C, pH 7.4
0.017
2-chloro-2'-deoxyadenosine
-
cosubstrate ATP, 37°C, pH 7.6
0.024
2-chloro-2'-deoxyadenosine
-
cosubstrate ATP, 37°C, pH 7.6
0.0051
2-chlorodeoxyadenosine
cosubstrate UTP, pH 7.5, 37°C
0.078
2-chlorodeoxyadenosine
cosubstrate ATP, pH 7.5, 37°C
0.02
4'-thio-beta-D-arabinofuranosylcytosine
-
cosubstrate UTP 37°C, pH 8.0
0.088
4'-thio-beta-D-arabinofuranosylcytosine
-
cosubstrate ATP 37°C, pH 8.0
2
9-beta-D-arabinofuranosylguanine
-
cosubstrate UTP, 37°C, pH 7.6
3
9-beta-D-arabinofuranosylguanine
-
cosubstrate UTP, 37°C, pH 7.6
3
9-beta-D-arabinofuranosylguanine
-
cosubstrate ATP, 37°C, pH 7.6
5
9-beta-D-arabinofuranosylguanine
-
cosubstrate ATP, 37°C, pH 7.6
0.001
ATP
-
cosubstrate 2'-deoxycytidine, 37°C, pH 7.4
0.0029
ATP
residues 65-79 deletion mutant with 2'-deoxycytidine as cosubstrate
0.0034
ATP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, wild-type, 37°C, pH 7.5
0.0035
ATP
wild type enzyme with 2'-deoxycytidine as cosubstrate
0.0084
ATP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.0132
ATP
cosubstrate troxacitabine, wild-type, 37°C, pH 7.5
0.019
ATP
wild type enzyme with 2'-deoxycytidine as phosphate acceptor, pH 7.6
0.025
ATP
C185A mutant enzyme with 2'-deoxycytidine as phosphate acceptor, pH 7.6
0.053
ATP
residues 65-79 deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.0568
ATP
cosubstrate troxacitabine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.087
ATP
C185A mutant enzyme with 2'-deoxyadenosine as phosphate acceptor, pH 7.6
0.093
ATP
wild type enzyme with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.097
ATP
wild type enzyme with 2'-deoxyadenosine as phosphate acceptor, pH 7.6
0.11
ATP
-
cosubstrate deoxycytidine, 37°C, pH 8.0
0.2
ATP
-
cosubstrate cytosine arabinoside, 37°C, pH 8.0
0.00041
beta-D-arabinofuranosylcytosine
-
cosubstrate UTP 37°C, pH 8.0
0.015
beta-D-arabinofuranosylcytosine
-
cosubstrate ATP 37°C, pH 8.0
0.00065
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.0016
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
0.0024
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.0155
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.0087
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.0155
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
0.022
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.0325
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.45
cytidine
-
37°C, pH 7.0
1.4
cytidine
-
37°C, pH 8.0
0.002
cytosine arabinoside
-
L-isomer, 25°C, pH 7.6
0.002
cytosine arabinoside
-
deoxycytidine, cytosolic isozyme I, pH 7.5, 37°C
0.007
cytosine arabinoside
-
cytosolic isozyme I, pH 7.5, 37°C
0.02 - 0.04
cytosine arabinoside
-
37°C, pH 8.0
0.02 - 0.04
cytosine arabinoside
-
pH 7.0, 37°C
0.02 - 0.04
cytosine arabinoside
-
pH 8.0, 37°C
0.02 - 0.04
cytosine arabinoside
-
pH 7.6, 25°C
0.02 - 0.04
cytosine arabinoside
-
D-isomer
0.02 - 0.04
cytosine arabinoside
-
D-isomer
0.0243
D-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.144
D-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.093
deoxyadenosine
at pH 8.0, temperature not specified in the publication
0.12
deoxyadenosine
-
pH 8.0, 37°C
0.15
deoxyadenosine
-
pH 8.0
0.5
deoxyadenosine
-
37°C, pH 7.0
0.553
deoxyadenosine
at pH 8.0, temperature not specified in the publication
0.89
deoxyadenosine
-
37°C, pH 7.5
0.00007
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.00009
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.00013
deoxycytidine
-
cosubstrate UTP 37°C, pH 8.0
0.00018
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
0.00027
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.00034
deoxycytidine
at pH 8.0, temperature not specified in the publication
0.00057
deoxycytidine
-
cosubstrate ATP 37°C, pH 8.0
0.0007
deoxycytidine
at pH 8.0, temperature not specified in the publication
0.0008 - 0.0015
deoxycytidine
-
pH 8.0, 37°C
0.0008 - 0.0015
deoxycytidine
-
37°C, pH 7.0
0.001
deoxycytidine
wild-type, pH 7.5, 37°C
0.001
deoxycytidine
wild-type, pH 7.5, 30°C
0.00104
deoxycytidine
mutant R104Q/D133G, pH 7.5, 30°C
0.00141
deoxycytidine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
0.00154
deoxycytidine
mutant A100V/R104M/D133A, pH 7.5, 37°C
0.002
deoxycytidine
mutant R104M/D133A, pH 7.5, 37°C
0.0033 - 0.0093
deoxycytidine
-
-
0.0033 - 0.0093
deoxycytidine
-
37°C, pH 8.0
0.00455
deoxycytidine
mutant R104M/D133S, pH 7.5, 37°C
0.00525
deoxycytidine
mutant A100V/R104M/D133S, pH 7.5, 37°C
0.00542
deoxycytidine
-
wild type enzyme, pH and temperature not specified in the publication
0.0086
deoxycytidine
mutant R104Q/D133N, pH 7.5, 30°C
0.0118
deoxycytidine
mutant R104M/D133N, pH 7.5, 37°C
0.014
deoxycytidine
-
37°C, pH 8.0
0.014 - 0.0167
deoxycytidine
-
pH 7.5, 37°C
0.014 - 0.0167
deoxycytidine
-
37°C, pH 8.0
0.014 - 0.0167
deoxycytidine
-
37°C, pH 8.0
0.014 - 0.0167
deoxycytidine
-
cytosine arabinoside-induced cells, 37°C, pH 8.0
0.014 - 0.0167
deoxycytidine
-
mitochondrial isozyme, pH 7.5, 37°C
0.0209
deoxycytidine
mutant R104M/D133T, pH 7.5, 37°C
0.071
deoxycytidine
mutant A100V/R104M/D133T, pH 7.5, 37°C
0.122
deoxyguanosine
at pH 8.0, temperature not specified in the publication
0.15
deoxyguanosine
-
pH 8.0, 37°C
0.33 - 0.43
deoxyguanosine
-
-
0.33 - 0.43
deoxyguanosine
-
37°C, pH 7.0
0.527
deoxyguanosine
at pH 8.0, temperature not specified in the publication
0.64
deoxyguanosine
-
37°C, pH 7.5
3
deoxyguanosine
-
37°C, pH 8.0
12.457
deoxythymidine
at pH 8.0, temperature not specified in the publication
18.546
deoxythymidine
at pH 8.0, temperature not specified in the publication
7.502
deoxyuridine
at pH 8.0, temperature not specified in the publication
15.081
deoxyuridine
at pH 8.0, temperature not specified in the publication
0.028
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.142
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
0.45
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.551
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.0161
gemcitabine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0338
gemcitabine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0467
gemcitabine
-
wild type enzyme, pH and temperature not specified in the publication
0.0562
gemcitabine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.0178
L-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.138
L-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.00388
thymidine
mutant A100V/R104M/D133T, pH 7.5, 37°C
0.00558
thymidine
mutant A100V/R104M/D133S, pH 7.5, 37°C
0.0058
thymidine
mutant R104M/D133T, pH 7.5, 37°C
0.0189
thymidine
mutant R104M/D133S, pH 7.5, 37°C
0.025
thymidine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
0.0256
thymidine
mutant R104M/D133N, pH 7.5, 37°C
0.0257
thymidine
mutant R104Q/D133G, pH 7.5, 30°C
0.031
thymidine
mutant A100V/R104M/D133A, pH 7.5, 37°C
0.036
thymidine
mutant R104Q/D133N, pH 7.5, 30°C
0.074
thymidine
mutant R104M/D133A, pH 7.5, 37°C
3.485
thymidine
wild-type, pH 7.5, 37°C
3.485
thymidine
wild-type, pH 7.5, 30°C
0.011
troxacitabine
wild type enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.013
troxacitabine
wild type enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.057
troxacitabine
C9S/C45S/C59S/C146S mutant enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.058
troxacitabine
C9S/C45S/C59S/C146Smutant enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.0005
UTP
-
cosubstrate 2'-deoxycytidine, 37°C, pH 7.4
0.0015
UTP
residues 65-79 deletion mutant with 2'-deoxycytidine as cosubstrate
0.0023
UTP
wild type enzyme deletion mutant with 2'-deoxycytidine as cosubstrate
0.0047
UTP
residues 65-79 deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.008
UTP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, wild-type, 37°C, pH 7.5
0.01
UTP
wild type enzyme deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.0106
UTP
cosubstrate troxacitabine, wild-type, 37°C, pH 7.5
0.011
UTP
wild type enzyme with 2'-deoxycytidine as phosphate acceptor, pH 7.6
0.0149
UTP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.017
UTP
C185A mutant enzyme with 2'-deoxycytidine as phosphate acceptor, pH 7.6
0.02
UTP
C185A mutant enzyme with 2'-deoxyadenosine as phosphate acceptor, pH 7.6
0.04
UTP
wild type enzyme with 2'-deoxyadenosine as phosphate acceptor, pH 7.6
0.0578
UTP
cosubstrate troxacitabine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
-
-
additional information
additional information
-
kinetic study
-
additional information
additional information
-
kinetic study
-
additional information
additional information
-
kinetic study
-
additional information
additional information
-
kinetic study
-
additional information
additional information
-
Km-values of D-and L-analogues of cytidine and adenosine
-
additional information
additional information
-
linear kinetics with deoxyguanosine or cytidine, bimodal kinetics with deoxycytidine as substrate
-
additional information
additional information
-
linear kinetics with deoxyguanosine or cytidine, bimodal kinetics with deoxycytidine as substrate
-
additional information
additional information
-
Km-values of D-and L-cytidine analogues
-
additional information
additional information
-
Km-values of a variety of substrate derivatives
-
additional information
additional information
no Michaelis-Menten kinetics, but negative cooperativity
-
additional information
additional information
-
steady-state fluorescent measurements, substrate binding constants, recombinant enzyme
-
additional information
additional information
kinetic properties of the enzyme are modulated in vivo by phosphorylation of Ser74, mechanism, overview
-
additional information
additional information
-
kinetic properties of the enzyme are modulated in vivo by phosphorylation of Ser74, mechanism, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.028 - 0.102
(-)-beta-2',3'-dideoxy-3'-thiacytidine
0.15 - 1.06
1-beta-D-arabinofuranosylcytosine
0.34 - 1.43
1-beta-D-arabinosylcytosine
0.44 - 1.21
2',2'-difluorodeoxycytidine
0.31 - 5.72
2'-deoxyadenosine
0.033 - 1.8
2'-deoxycytidine
0.31 - 4.38
2'-deoxyguanosine
0.02
2,5-difluoro-4-[1-(2-deoxy-beta-L-ribofuranosyl)]-aniline
-
pH 7.6, 37°C, recombinant enzyme
0.37 - 0.6
2-chlorodeoxyadenosine
0.0804 - 1.386
cladribine
0.38
cytarabine
-
wild type enzyme, pH and temperature not specified in the publication
2.73 - 4.07
deoxyadenosine
0.015 - 78300
deoxycytidine
1.23 - 3.4
deoxyguanosine
0.29 - 1.08
deoxythymidine
0.177 - 1.334
fludarabine
0.095 - 0.524
troxacitabine
0.028
(-)-beta-2',3'-dideoxy-3'-thiacytidine
C9S/C45S/C59S/C146S mutant enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.03
(-)-beta-2',3'-dideoxy-3'-thiacytidine
wild type enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.072
(-)-beta-2',3'-dideoxy-3'-thiacytidine
C9S/C45S/C59S/C146S mutant enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.102
(-)-beta-2',3'-dideoxy-3'-thiacytidine
wild type enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.15
1-beta-D-arabinofuranosylcytosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.17
1-beta-D-arabinofuranosylcytosine
wild type enzyme with UTP as cosubstrate
0.3
1-beta-D-arabinofuranosylcytosine
wild type enzyme with ATP as cosubstrate
0.3
1-beta-D-arabinofuranosylcytosine
mutant S74Q, pH 7.5, 25°C
0.32
1-beta-D-arabinofuranosylcytosine
wild-type, pH 7.5, 25°C
0.33
1-beta-D-arabinofuranosylcytosine
mutant S74A, pH 7.5, 25°C
0.41
1-beta-D-arabinofuranosylcytosine
residues 65-79 deletion mutant with ATP as cosubstrate
0.57
1-beta-D-arabinofuranosylcytosine
mutant S74D, pH 7.5, 25°C
1.06
1-beta-D-arabinofuranosylcytosine
mutant S74E, pH 7.5, 25°C
0.34
1-beta-D-arabinosylcytosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.79
1-beta-D-arabinosylcytosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
1.43
1-beta-D-arabinosylcytosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.44
2',2'-difluorodeoxycytidine
wild-type, pH 7.5, 25°C
0.45
2',2'-difluorodeoxycytidine
mutant S74Q, pH 7.5, 25°C
0.5
2',2'-difluorodeoxycytidine
mutant S74A, pH 7.5, 25°C
0.9
2',2'-difluorodeoxycytidine
mutant S74D, pH 7.5, 25°C
1.21
2',2'-difluorodeoxycytidine
mutant S74E, pH 7.5, 25°C
0.31
2'-deoxyadenosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.33
2'-deoxyadenosine
wild type enzyme with UTP as cosubstrate
0.37
2'-deoxyadenosine
cosubstrate UTP, pH 7.5, 37°C
0.69
2'-deoxyadenosine
mutant S74E, pH 7.5, 25°C
0.77
2'-deoxyadenosine
wild-type, pH 7.5, 25°C
0.9
2'-deoxyadenosine
mutant S74Q, pH 7.5, 25°C
1
2'-deoxyadenosine
mutant S74D, pH 7.5, 25°C
1.08
2'-deoxyadenosine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
1.12
2'-deoxyadenosine
mutant S74A, pH 7.5, 25°C
1.7
2'-deoxyadenosine
wild type enzyme with ATP as cosubstrate
1.75
2'-deoxyadenosine
mutant R104Q/D133G, pH 7.5, 30°C
2
2'-deoxyadenosine
mutant R104Q/D133N, pH 7.5, 30°C
2.1
2'-deoxyadenosine
cosubstrate ATP, pH 7.5, 37°C
2.13
2'-deoxyadenosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
2.67
2'-deoxyadenosine
mutant A100V/R104M/D133T, pH 7.5, 37°C
2.71
2'-deoxyadenosine
mutant R104M/D133A, pH 7.5, 37°C
2.8
2'-deoxyadenosine
residues 65-79 deletion mutant with ATP as cosubstrate
3.1
2'-deoxyadenosine
wild-type, pH 7.5, 37°C
3.1
2'-deoxyadenosine
wild-type, pH 7.5, 30°C
3.37
2'-deoxyadenosine
mutant A100V/R104M/D133S, pH 7.5, 37°C
3.4
2'-deoxyadenosine
mutant A100V/R104M/D133A, pH 7.5, 37°C
3.47
2'-deoxyadenosine
mutant R104M/D133N, pH 7.5, 37°C
4.14
2'-deoxyadenosine
mutant R104M/D133T, pH 7.5, 37°C
4.51
2'-deoxyadenosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
4.85
2'-deoxyadenosine
mutant R104M/D133S, pH 7.5, 37°C
5.72
2'-deoxyadenosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.033
2'-deoxycytidine
less than 0.001 mM, wild type enzyme with ATP as cosubstrate
0.04
2'-deoxycytidine
wild-type, pH 7.5, 25°C
0.04
2'-deoxycytidine
mutant S74A, pH 7.5, 25°C
0.04
2'-deoxycytidine
mutant S74Q, pH 7.5, 25°C
0.04
2'-deoxycytidine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.044
2'-deoxycytidine
less than 0.001 mM, wild type enzyme with UTP as cosubstrate
0.049
2'-deoxycytidine
residues 65-79 deletion mutant with ATP as cosubstrate
0.088
2'-deoxycytidine
less than 0.001 mM, residues 65-79 deletion mutant with UTP as cosubstrate
0.11
2'-deoxycytidine
-
pH 7.6, 37°C, recombinant enzyme
0.16
2'-deoxycytidine
mutant S74D, pH 7.5, 25°C
0.25
2'-deoxycytidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.45
2'-deoxycytidine
mutant S74E, pH 7.5, 25°C
1.8
2'-deoxycytidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.31
2'-deoxyguanosine
mutant A100V/R104M/D133A, pH 7.5, 37°C
0.32
2'-deoxyguanosine
residues 65-79 deletion mutant with UTP as cosubstrate
0.33
2'-deoxyguanosine
wild type enzyme with UTP as cosubstrate
0.36
2'-deoxyguanosine
mutant S74E, pH 7.5, 25°C
0.53
2'-deoxyguanosine
cosubstrate UTP, pH 7.5, 37°C
0.57
2'-deoxyguanosine
mutant S74D, pH 7.5, 25°C
0.65
2'-deoxyguanosine
mutant S74Q, pH 7.5, 25°C
0.68
2'-deoxyguanosine
mutant S74A, pH 7.5, 25°C
0.73
2'-deoxyguanosine
wild-type, pH 7.5, 25°C
1.18
2'-deoxyguanosine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
1.23
2'-deoxyguanosine
mutant R104M/D133A, pH 7.5, 37°C
1.5
2'-deoxyguanosine
mutant R104Q/D133G, pH 7.5, 30°C
1.72
2'-deoxyguanosine
mutant A100V/R104M/D133S, pH 7.5, 37°C
1.73
2'-deoxyguanosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
1.92
2'-deoxyguanosine
mutant R104Q/D133N, pH 7.5, 30°C
2.2
2'-deoxyguanosine
residues 65-79 deletion mutant with ATP as cosubstrate
2.29
2'-deoxyguanosine
mutant A100V/R104M/D133T, pH 7.5, 37°C
2.5
2'-deoxyguanosine
cosubstrate ATP, pH 7.5, 37°C
2.5
2'-deoxyguanosine
mutant R104M/D133T, pH 7.5, 37°C
2.6
2'-deoxyguanosine
wild type enzyme with ATP as cosubstrate
2.6
2'-deoxyguanosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
3.26
2'-deoxyguanosine
wild-type, pH 7.5, 37°C
3.26
2'-deoxyguanosine
wild-type, pH 7.5, 30°C
3.59
2'-deoxyguanosine
mutant R104M/D133N, pH 7.5, 37°C
3.66
2'-deoxyguanosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
4.38
2'-deoxyguanosine
mutant R104M/D133S, pH 7.5, 37°C
0.37
2-chlorodeoxyadenosine
cosubstrate UTP, pH 7.5, 37°C
0.6
2-chlorodeoxyadenosine
cosubstrate ATP, pH 7.5, 37°C
0.012
ATP
cosubstrate L-2'-deoxycytidine, wild-type, 37°C, pH 7.5
0.028
ATP
wild type enzyme with 2'-deoxycytidine as cosubstrate
0.028
ATP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.03
ATP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, wild-type, 37°C, pH 7.5
0.033
ATP
cosubstrate D-2'-deoxycytidine, wild-type, 37°C, pH 7.5
0.036
ATP
cosubstrate L-2'-deoxycytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.039
ATP
residues 65-79 deletion mutant with 2'-deoxycytidine as cosubstrate
0.095
ATP
cosubstrate troxacitabine, wild-type, 37°C, pH 7.5
0.173
ATP
cosubstrate D-2'-deoxycytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.192
ATP
cosubstrate troxacitabine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.36
ATP
residues 65-79 deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.4
ATP
wild type enzyme with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.0804
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.172
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.211
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
1.386
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.486
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.88
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
1.11
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
2.45
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
1.74
D-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
3.2
D-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
2.73
deoxyadenosine
at pH 8.0, temperature not specified in the publication
4.07
deoxyadenosine
at pH 8.0, temperature not specified in the publication
0.015
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.021
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.035
deoxycytidine
-
wild type enzyme, pH and temperature not specified in the publication
0.05
deoxycytidine
at pH 8.0, temperature not specified in the publication
0.064
deoxycytidine
wild-type, pH 7.5, 37°C
0.064
deoxycytidine
wild-type, pH 7.5, 30°C
0.09
deoxycytidine
at pH 8.0, temperature not specified in the publication
0.123
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
0.183
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
0.21
deoxycytidine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
0.37
deoxycytidine
mutant R104Q/D133G, pH 7.5, 30°C
0.58
deoxycytidine
mutant R104M/D133A, pH 7.5, 37°C
1.2
deoxycytidine
mutant A100V/R104M/D133A, pH 7.5, 37°C
1.3
deoxycytidine
mutant R104Q/D133N, pH 7.5, 30°C
1.7
deoxycytidine
mutant R104M/D133S, pH 7.5, 37°C
2.1
deoxycytidine
mutant A100V/R104M/D133S, pH 7.5, 37°C
2.23
deoxycytidine
mutant R104M/D133N, pH 7.5, 37°C
2.86
deoxycytidine
mutant R104M/D133T, pH 7.5, 37°C
3.54
deoxycytidine
mutant A100V/R104M/D133T, pH 7.5, 37°C
1330
deoxycytidine
-
cytosine arabinoside-induced cells
1.23
deoxyguanosine
at pH 8.0, temperature not specified in the publication
3.4
deoxyguanosine
at pH 8.0, temperature not specified in the publication
0.29
deoxythymidine
at pH 8.0, temperature not specified in the publication
1.08
deoxythymidine
at pH 8.0, temperature not specified in the publication
1.05
deoxyuridine
at pH 8.0, temperature not specified in the publication
1.27
deoxyuridine
at pH 8.0, temperature not specified in the publication
0.177
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
0.363
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
1.005
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
1.334
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
0.39
gemcitabine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.57
gemcitabine
-
wild type enzyme, pH and temperature not specified in the publication
2.01
gemcitabine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
2.68
gemcitabine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
1.33
L-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
3.13
L-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.38
thymidine
wild-type, pH 7.5, 37°C
0.38
thymidine
wild-type, pH 7.5, 30°C
0.68
thymidine
mutant D47E/R104Q/D133G/N163I/F242L, pH 7.5, 30°C
1.01
thymidine
mutant R104Q/D133G, pH 7.5, 30°C
1.49
thymidine
mutant R104M/D133T, pH 7.5, 37°C
1.51
thymidine
mutant R104Q/D133N, pH 7.5, 30°C
1.57
thymidine
mutant A100V/R104M/D133T, pH 7.5, 37°C
1.88
thymidine
mutant R104M/D133A, pH 7.5, 37°C
1.91
thymidine
mutant A100V/R104M/D133S, pH 7.5, 37°C
2.27
thymidine
mutant R104M/D133N, pH 7.5, 37°C
2.33
thymidine
mutant R104M/D133S, pH 7.5, 37°C
3.29
thymidine
mutant A100V/R104M/D133A, pH 7.5, 37°C
0.095
troxacitabine
wild type enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.179
troxacitabine
wild type enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.192
troxacitabine
C9S/C45S/C59S/C146S mutant enzyme with ATP as phosphate donor, 37°C, pH 7.5
0.524
troxacitabine
C9S/C45S/C59S/C146S mutant enzyme with UTP as phosphate donor, 37°C, pH 7.5
0.01
UTP
cosubstrate L-2'-deoxycytidine, wild-type, 37°C, pH 7.5
0.031
UTP
wild type enzyme deletion mutant with 2'-deoxycytidine as cosubstrate
0.041
UTP
residues 65-79 deletion mutant with 2'-deoxycytidine as cosubstrate
0.042
UTP
cosubstrate L-2'-deoxycytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.049
UTP
cosubstrate D-2'-deoxycytidine, wild-type, 37°C, pH 7.5
0.072
UTP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.075
UTP
residues 65-79 deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.093
UTP
wild type enzyme deletion mutant with 1-beta-D-arabinofuranosylcytosine as cosubstrate
0.102
UTP
cosubstrate (-)-beta-2',3'-dideoxy-3'-thiacytidine, wild-type, 37°C, pH 7.5
0.179
UTP
cosubstrate troxacitabine, wild-type, 37°C, pH 7.5
0.217
UTP
cosubstrate D-2'-deoxycytidine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
0.524
UTP
cosubstrate troxacitabine, mutant C9S/C45S/C59S/C146S, 37°C, pH 7.5
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
10.5 - 26
1-beta-D-arabinosylcytosine
4.3 - 35.2
2'-deoxyadenosine
13.3 - 315.8
2'-deoxycytidine
0.9 - 11.3
2'-deoxyguanosine
13.48
cytarabine
-
wild type enzyme, pH and temperature not specified in the publication
4.94 - 43.8
deoxyadenosine
6.44 - 10.1
deoxyguanosine
0.0236 - 0.0581
deoxythymidine
0.084 - 0.14
deoxyuridine
10.5
1-beta-D-arabinosylcytosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
15.6
1-beta-D-arabinosylcytosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
26
1-beta-D-arabinosylcytosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
4.3
2'-deoxyadenosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
18.6
2'-deoxyadenosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
35.2
2'-deoxyadenosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
13.3
2'-deoxycytidine
kcat/Km above 13.3/sec*mM, wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
31.3
2'-deoxycytidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
315.8
2'-deoxycytidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
0.9
2'-deoxyguanosine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
1.6
2'-deoxyguanosine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
11.3
2'-deoxyguanosine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
74.3
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
90.2
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
130
cladribine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
136
cladribine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
50.1
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
56.3
clofarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
57.6
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
76.8
clofarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
12.1
D-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
131.7
D-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
4.94
deoxyadenosine
at pH 8.0, temperature not specified in the publication
43.8
deoxyadenosine
at pH 8.0, temperature not specified in the publication
6.46
deoxycytidine
-
wild type enzyme, pH and temperature not specified in the publication
65.9
deoxycytidine
at pH 8.0, temperature not specified in the publication
236
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
257
deoxycytidine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
259
deoxycytidine
at pH 8.0, temperature not specified in the publication
676
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
745
deoxycytidine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
6.44
deoxyguanosine
at pH 8.0, temperature not specified in the publication
10.1
deoxyguanosine
at pH 8.0, temperature not specified in the publication
0.0236
deoxythymidine
at pH 8.0, temperature not specified in the publication
0.0581
deoxythymidine
at pH 8.0, temperature not specified in the publication
0.084
deoxyuridine
at pH 8.0, temperature not specified in the publication
0.14
deoxyuridine
at pH 8.0, temperature not specified in the publication
1.8
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate ATP
2.6
fludarabine
-
pH 7.6, 37°C, enzyme mutant S74E, with co-substrate UTP
3
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate ATP
6.4
fludarabine
-
pH 7.6, 37°C, wild-type enzyme, with co-substrate UTP
12.21
gemcitabine
-
wild type enzyme, pH and temperature not specified in the publication
24.2
gemcitabine
wild type enzyme, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
47.7
gemcitabine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
59.5
gemcitabine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
22.7
L-thymidine
mutant enzyme R104M/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
74.7
L-thymidine
mutant enzyme R104L/D133A, in 100 mM Tris, pH 7.5, 100 mM KCl, 10 mM MgCl2 and 1 mM ATP, at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00012
2'-deoxy-5-fluorocytidine
Mus musculus
-
-
0.000003
2-(2-[1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]ethoxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000034
2-([1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]methoxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000038
2-([1-[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000003
2-([1-[6-(2-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.00001
2-([1-[6-(2-ethylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000022
2-([1-[6-(3-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000009
2-([1-[6-(4-chloro-2-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000019
2-([1-[6-(4-chlorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000003
2-([1-[6-(biphenyl-2-yloxy)pyrimidin-4-yl]piperidin-4-yl]oxy)-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000063
2-([6-[4-(4-amino-2-oxopyrimidin-1(2H)-yl)piperidin-1-yl]-5-fluoropyrimidin-4-yl]oxy)benzonitrile
Mus musculus
-
-
0.00167
2-([[2-(3-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
Homo sapiens
at pH 7.6 and 37°C
0.00112
2-([[2-(4-ethoxy-3-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
Homo sapiens
at pH 7.6 and 37°C
0.1
2-([[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine
Homo sapiens
IC50 above 0.1 mM, at pH 7.6 and 37°C
0.00202
2-([[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
Homo sapiens
at pH 7.6 and 37°C
0.00232
2-([[2-(4-methylphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
Homo sapiens
at pH 7.6 and 37°C
0.00176
2-([[2-(5-bromo-2-methoxyphenyl)-1,3-thiazol-4-yl]methyl]sulfanyl)pyrimidine-4,6-diamine
Homo sapiens
at pH 7.6 and 37°C
0.0007457
2-[(2[-[3-(2-fluoroethoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
Homo sapiens
pH and temperature not specified in the publication
0.000005
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-bromopyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.00001
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-methylpyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.000002
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]-5-methoxybenzonitrile
Mus musculus
-
-
0.000001
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.000021
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-methylpyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.000003
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]-5-methoxybenzonitrile
Mus musculus
-
-
0.000003
2-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.0000007
2-[(6-[4-[(4-aminopyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.0000263
2-[([2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-methyl-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
Homo sapiens
pH and temperature not specified in the publication
0.0000167
2-[([2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-5-propyl-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
Homo sapiens
pH and temperature not specified in the publication
0.0000227
2-[([5-ethyl-2-[3-(2-fluoroethoxy)-4-methoxyphenyl]-1,3-thiazol-4-yl]methyl)sulfanyl]pyrimidine-4,6-diamine
Homo sapiens
pH and temperature not specified in the publication
0.1
2-[[(2-phenyl-1,3-thiazol-4-yl)methyl]sulfanyl]pyrimidine
Homo sapiens
IC50 above 0.1 mM, at pH 7.6 and 37°C
0.00072
2-[[6-(1-benzothiophen-2-yl)pyrimidin-4-yl]oxy]-5-fluoropyrimidin-4-amine
Mus musculus
-
-
0.000089
3'-[[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]sulfamoyl]biphenyl-4-carboxamide
Homo sapiens
-
0.000001
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-2-fluoropyrimidin-4-yl)oxy]-4-methoxybenzonitrile
Mus musculus
-
-
0.000005
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]-4-methoxybenzonitrile
Mus musculus
-
-
0.000004
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]-5-fluoropyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.000013
3-[(6-[4-[(4-amino-5-fluoropyrimidin-2-yl)oxy]piperidin-1-yl]pyrimidin-4-yl)oxy]benzonitrile
Mus musculus
-
-
0.000024
4'-thio-beta-D-arabinofuranosylcytosine
Homo sapiens
-
IC50 0.000024 mM
0.00051
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
0.051
5-chloro-4'-thio-beta-D-arabinofuranosylcytosine
Homo sapiens
-
IC50 0.051 mM
0.00012
5-Fluoro-2'-deoxycytidine
Homo sapiens
-
0.000004
5-fluoro-2-([1-[5-fluoro-6-(4-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000006
5-fluoro-2-([1-[6-(2-fluorophenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000005
5-fluoro-2-([1-[6-(2-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000009
5-fluoro-2-([1-[6-(2-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000023
5-fluoro-2-([1-[6-(3-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000033
5-fluoro-2-([1-[6-(4-methoxyphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000021
5-fluoro-2-([1-[6-(4-methylphenoxy)pyrimidin-4-yl]piperidin-4-yl]oxy)pyrimidin-4-amine
Mus musculus
-
-
0.000095
5-fluoro-2-[[1-(6-phenoxypyrimidin-4-yl)piperidin-4-yl]oxy]pyrimidin-4-amine
Mus musculus
-
-
0.000002
5-fluoro-4'-thio-beta-D-arabinofuranosylcytosine
Homo sapiens
-
IC50 0.0000020 mM
0.0000055
cytosine arabinoside
Homo sapiens
-
IC50 0.0000055 mM
0.0138
LP-375752
Homo sapiens
-
in 50 mM Tris (pH 7.6)
0.00091
LP-503392
Homo sapiens
-
in 50 mM Tris (pH 7.6)
0.000021
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-2',4'-dichlorobiphenyl-3-sulfonamide
Homo sapiens
-
0.000045
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-2'-chlorobiphenyl-3-sulfonamide
Homo sapiens
-
0.000023
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3'-chlorobiphenyl-3-carboxamide
Homo sapiens
-
0.000079
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3'-chlorobiphenyl-3-sulfonamide
Homo sapiens
-
0.00035 - 0.0019
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3-bromobenzenesulfonamide
0.000021
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4''-chloro-2''-methyl-1,1':4',1''-terphenyl-3-carboxamide
Homo sapiens
-
0.000021
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4''-chloro-2''-methyl-1,1':4',1''-terphenyl-3-sulfonamide
Homo sapiens
-
0.000063
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-(methylsulfonyl)biphenyl-3-sulfonamide
Homo sapiens
-
0.000051
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-chlorobiphenyl-3-sulfonamide
Homo sapiens
-
0.000049
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-cyanobiphenyl-3-sulfonamide
Homo sapiens
-
0.0153
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-formylbiphenyl-3-sulfonamide
Homo sapiens
-
0.00003 - 0.000042
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-carboxamide
0.000064
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-sulfonamide
Homo sapiens
-
0.00011
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methylbiphenyl-3-sulfonamide
Homo sapiens
-
0.0000017
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-(1-benzothiophen-2-yl)pyridine-2-carboxamide
Homo sapiens
-
0.0027
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-bromobenzenesulfonamide
Homo sapiens
-
0.0032
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4-nitrobenzenesulfonamide
Homo sapiens
-
0.0036
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]benzenesulfonamide
Homo sapiens
-
0.00026
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]biphenyl-3-carboxamide
Homo sapiens
-
0.00012
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]biphenyl-3-sulfonamide
Homo sapiens
-
0.00051
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
Mus musculus
-
-
0.00051
4-(1-benzothiophen-2-yl)-6-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]pyrimidine
Homo sapiens
-
0.00035
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3-bromobenzenesulfonamide
Homo sapiens
-
0.0019
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-3-bromobenzenesulfonamide
Homo sapiens
-
0.00003
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-carboxamide
Homo sapiens
-
0.000042
N-[(1S,3S)-3-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)cyclopentyl]-4'-methoxybiphenyl-3-carboxamide
Homo sapiens
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
A100V/R104M/D133S/E196A
the mutant shows low activity for D-deoxycytidine and D-thymidine
A100V/R104M/D133S/E196L
inactive
A100V/R104M/D133S/F96D
inactive
A100V/R104M/D133S/F96Y
the mutant shows low activity for D-deoxycytidine and D-thymidine
A100V/R104M/D133S/W58E
inactive
A100V/R104M/D133S/W58V
the mutant shows low activity for D-deoxycytidine and D-thymidine
A100V/R104M/D133T
ratio kcat/Km for deoxycytidine similar to wild-type
C185A
lower efficiency with dCyd as the substrate with ATP und UTP, nearly 2-fold higher efficiency than wild-type dCK with dAdo as substrate and UTP as the phosphate donor
C9S/C45S/C59S/S74E/R104M/D133A/C146S
site-directed mutagenesis, crystallization mutant
D47E/R104Q/D133G/N163I/F242L
1.5fold increase in ratio kcat/Km for deoxycytidine
DEL65-79
construction of an enzyme variant lacking a flexible insert (residues 65-79) but having similar catalytic properties as the wild type
R104I/D133A
site-directed mutagenesis, the mutations render the enzyme active with 5-substituted deoxycytidine and thymidine, altered substrate specificity compared to the wild-type enzyme
R104M/D133A/S74E
-
site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme
R104M/D133N/A138I
inactive
R104M/D133N/L102Y
the mutant shows low activity for D-deoxycytidine and D-thymidine
R104M/D133N/L191A
the mutant shows low activity for D-deoxycytidine and D-thymidine
R104M/D133N/M85Y
the mutant shows low activity for D-deoxycytidine and D-thymidine
R104M/D133N/P89F
inactive
R104M/D133N/V130T
the mutant shows low activity for D-deoxycytidine and D-thymidine
R104M/D133N/V130T/L191A
the mutant shows low activity for D-deoxycytidine and D-thymidine
R104M/D133N/V55E
the mutant shows very low activity for D-deoxycytidine and D-thymidine
R104M/D133N/V55F
the mutant shows very low activity for D-deoxycytidine and D-thymidine
R104M/D133N/V55F/V130T
the mutant shows very low activity for D-deoxycytidine and D-thymidine
R104M/D133N/V55F/V130T/L191A
the mutant shows very low activity for D-deoxycytidine and D-thymidine
R104M/D133S
6fold increase in ratio kcat/Km for deoxycytidine
R104M/D133T
mutant with reversed substrate specificity, with elevated specific constant for thymidine phosphorylation and decreased activity for deeoxycytidine, deoxyadenosine, and deoxyguanosine
R104Q/D133A
site-directed mutagenesis, the mutations render the enzyme active with 5-substituted deoxycytidine and thymidine, altered substrate specificity compared to the wild-type enzyme
R104Q/D133G
mutant is a generalist kinase with broader specificity and elevated turnover compared with wild-type
R104Q/D133N
1.5fold increase in ratio kcat/Km for deoxycytidine
S74D
2-4fold lower kcat values
S74Q
no significant change in kcat for any of the substrates tested
A100V/R104M/D133A
site-directed mutagenesis, mutations alter the residues to the multisubstrate nucleoside kinase, EC 2.7.1.145, mutant shows 30fold increased kcat for deoxycytidine compared to the wild-type enzyme
A100V/R104M/D133A
12fold increase in ratio kcat/Km for deoxycytidine
A100V/R104M/D133S
6fold increase in ratio kcat/Km for deoxycytidine
A100V/R104M/D133S
the mutant shows exquisitely high activity for D-deoxycytidine and D-thymidine
A119G
naturally occurring mutation, 66% of activity of the wild type protein
A119G
genetic polymorphism, 66% of wild-type activity, decrease in Km value
C9S/C45S/C59S/C146S
engineered protein has a significantly improved crystallization behaviour compared with the wild type protein
C9S/C45S/C59S/C146S
mutation of the four surface-exposed Cys residues, constructued for crystallization. Mutant displays moderate kinetic differences in the catalytic efficiency when compared with wild-type
C9S/C45S/C59S/C146S
-
mutation of the four surface-exposed Cys residues, constructued for crystallization. Mutant displays moderate kinetic differences in the catalytic efficiency when compared with wild-type
D133A
-
site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme
D133A
site-directed mutagenesis, the mutation renders the enzyme capable of thymidine binding
I24V
naturally occurring mutation, 85% of activity of the wild type protein
I24V
genetic polymorphism, 85% of wild-type activity
P122S
naturally occurring mutation, 43% of activity of the wild type protein
P122S
genetic polymorphism, 43% of wild-type activity, decrease in Km value
P122S
-
the mutant shows reduced enzyme activity
R104L/D133A
the double mutant does also accept L- and D-thymidine as substrates
R104L/D133A
site-directed mutagenesis, the mutations render the enzyme active with 5-substituted deoxycytidine and thymidine, altered substrate specificity compared to the wild-type enzyme
R104M
-
site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme
R104M
site-directed mutagenesis, the mutation renders the enzyme capable of thymidine binding
R104M/D133A
site-directed mutagenesis, mutations alter the residues to the multisubstrate nucleoside kinase, EC 2.7.1.145, the mutant gains the ability to phosphorylate deoxythymidine
R104M/D133A
4fold increase in ratio kcat/Km for deoxycytidine
R104M/D133A
the double mutant is a pyrimidine-specific enzyme due to large Km values with purines and does also accept L- and D-thymidine as substrates
R104M/D133A
site-directed mutagenesis, the mutations render the enzyme active with 5-substituted deoxycytidine and thymidine, altered substrate specificity compared to the wild-type enzyme
R104M/D133N
3fold increase in ratio kcat/Km for deoxycytidine
R104M/D133N
the mutant shows low activity for D-deoxycytidine and D-thymidine
S11A
no significant effect on activity
S11A
-
site-directed mutagenesis, replacement of the phosphorylation site
S11E
no significant effect on activity
S11E
-
site-directed mutagenesis, replacement of the phosphorylation site
S15A
no significant effect on activity
S15A
-
site-directed mutagenesis, replacement of the phosphorylation site
S15E
no significant effect on activity
S15E
-
site-directed mutagenesis, replacement of the phosphorylation site, the mutant shows a slight, but significant, reduction of Ser74 phosphorylation
S74A
-
site-directed mutagenesis
S74A
mutation markedly decreases activity
S74A
6-8fold lower activity than wild-type
S74A
the mutation abrogates phosphorylation of the protein
S74A
the mutation abrogates phosphorylation of the protein. The ratio of phospho-Akt/Akt, phospho-mTOR/mTOR, phospho-P70S6K/P70S6K does not significantly decrease in mutant cells following ionizing radiation treatment
S74E
-
site-directed mutagenesis
S74E
mutation does not significantly modify dCK activity
S74E
mutation mimicking phosphorylation, results in 11fold increase in kcat value for deoxycytidine. Mutation has no effect on cellular localization
S74E
site-directed mutagenesis, replacing the serine with a glutamic acid mimic phosphorylation of Ser74, the enzyme containing the S74E mutation adopts the open state, but wild-type dCK can adopt the open state also in the absence of the S74E mutation
S74E
-
site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme
S74E
-
site-directed mutagenesis, the mutation sensitizes the enzyme to feedback inhibition by dCTP, regardless of the phosphoryl donor. Mimicking Ser74 phosphorylation by a S74E mutation increases the enzyme activity toward pyrimidine analogues. The S74E mutation increased the kcat for cladribine by 8 or 3fold, depending on whether the phosphoryl donor was ATP or UTP, for clofarabine by about 2fold with both ATP and UTP, and for fludarabine by 2fold, but only with UTP
S74E
the mutation mimics phosphorylation of the protein
S74E
the mutation mimics phosphorylation of the protein. The ratio of phospho-Akt/Akt, phospho-mTOR/mTOR, phospho-P70S6K/P70S6K significantly decreases in mutant cells following ionizing radiation treatment
T3A
no significant effect on activity
T3A
-
site-directed mutagenesis, replacement of the phosphorylation site, the mutant shows a slight, but significant, reduction of Ser74 phosphorylation
T3E
no significant effect on activity
T3E
-
site-directed mutagenesis, replacement of the phosphorylation site, the mutant shows a slight, but significant, reduction of Ser74 phosphorylation
additional information
-
in gemcitabine-resistant pancreatic cancer cells, expression of deoxycytidine kinase is significantly reduced compared with that of parental cells. Treatment with siRNA targeted to deoxycytidine kinase reduces gemcitabine sensitivity without affecting cell proliferation. Downregulation of gemcitabine-related genes RRM1 and RRM2 by siRNA increases gemcitabine sensitivity and reduces cell proliferation even without gemcitabine treatment
additional information
R104 and D133 are key residues for substrate specificity
additional information
-
R104 and D133 are key residues for substrate specificity
additional information
sequencing of deoxycytidine kinase and cytidine monophosphate kinase using 240 DNA samples reveals 28 polymorphisms in deoxycytidine kinase. Variant allozyme enzyme activities range from 32% to 105% of the wild type activity with no significant differences in apparent Km values except for a V24/S122 double variant enzyme. Relative levels of immunoreactive protein after expression in COS-1 cells parallel relative levels of enzyme activity
additional information
-
sequencing of gene from European and African individuals reveals 64 genetic polymorphisms. In general, African ancestry subjects show higher mRNA expression compared with subjects with European ancestry. In both groups, single nucleotide polymorphism 35708 C>T of a 3'-untranslated region is significanlty associated with lower mRNA expression and with lower blast 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in acute myeloid leukemia patients
additional information
sequencing of gene from European and African individuals reveals 64 genetic polymorphisms. In general, African ancestry subjects show higher mRNA expression compared with subjects with European ancestry. In both groups, single nucleotide polymorphism 35708 C>T of a 3'-untranslated region is significanlty associated with lower mRNA expression and with lower blast 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in acute myeloid leukemia patients
additional information
-
cotruction of a loss-of--function mutant dCK containing an altered ATP-binding site
additional information
-
mutants of dCK with rationally designed active sites, that make them thymidine-activating, are stably introduced into cells by recombinant lentiviral vectors. Transduced cells maintain growth kinetics and function. These dCK mutants efficiently activate bromovinyl-deoxyuridine, L-deoxythymidine, and L-deoxyuridine, which are otherwise not toxic to wild-type cells, overview. Mutant dCK-expressing Jurkat, Molt-4, and U87-MG cells could be efficiently eliminated in vitro and in xenogeneic leukemia and tumor models in vivo
additional information
-
stable enzyme knockout in HeLa cells by expression of dCK-siRNA or shRNA
additional information
-
deletion of exon 3 inactivates dCK function. Generation of enzyme knockout mice that show 90fold decrease in thymic cellularity compared to wild-type, lymphocyte numbers in the dCK KO mice are 5 to 13fold below normal values
additional information
-
for enzyme knockout, MLE12 cells are transfected with DCK siRNA
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.